|
|
|
|
|
Jessica Imbrescia, Giulia Volpi, Silvia Lucchini, Cristian Toraci, Giorgio Facheris, Salvatore La Mattina, Navdeep Singh, Filippo Vaccher, Andrea Guerini, Michela Buglione di Monale e Bastia, Alessio Bruni and Paolo Borghetti
Background: The standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is represented by concomitant chemo-radiotherapy followed by consolidation with durvalumab that ensures a 5-year survival of 46%. However, the risk of radiother...
ver más
|
|
|
|
|
|
|
|
|
|
|
Joana Morgado, Tania Pereira, Francisco Silva, Cláudia Freitas, Eduardo Negrão, Beatriz Flor de Lima, Miguel Correia da Silva, António J. Madureira, Isabel Ramos, Venceslau Hespanhol, José Luis Costa, António Cunha and Hélder P. Oliveira
The evolution of personalized medicine has changed the therapeutic strategy from classical chemotherapy and radiotherapy to a genetic modification targeted therapy, and although biopsy is the traditional method to genetically characterize lung cancer tum...
ver más
|
|
|
|
|
|